AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17704347 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 12 weeks)
Number of subjects: 20
Study 17704347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15725695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d)
Number of subjects: 46
Study 15725695 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 mg/d)
Number of subjects: 46
Study 15725695 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d) after crossover to Pravastatin
Number of subjects: 46
Study 15725695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/d) after crossover to Fluvastatin
Number of subjects: 46
Study 15725695 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (20 mg/d) and Pravastatin (10 mg/d)
Number of subjects: 46
Study 11943524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-rapacuronium
Number of subjects: 40
Study 11943524 — intervention group
Group type: COMPARATOR
Intervention: Propofol-rapacuronium
Number of subjects: 40
Study 9808220 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary mixture of 6 monoterpenes in olive oil
Number of subjects: 24
Study 9808220 — intervention group
Group type: COMPARATOR
Intervention: Olive oil alone
Number of subjects: 24
Study 8595682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (50 mg) in the deltoid
Number of subjects: 60
Study 8595682 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) in the deltoid and NS in the wound (Control Group C)
Number of subjects: 60
Study 8595682 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with meperidine (50 mg)
Number of subjects: 60
Study 2653846 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + endocrine therapy
Number of subjects: 363
Study 2653846 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + chemotherapy
Number of subjects: 363
Study 2653846 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy + endocrine therapy + chemotherapy
Number of subjects: 363
Study 2653846 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 363
Study 2653846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hormone treatment and chemotherapy
Number of subjects: 363
Study 1188710 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg)
Number of subjects: 20
Study 1188710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31594431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (1-year duration)
Number of subjects: 1561
Study 31594431 — intervention group
Group type: COMPARATOR
Intervention: Weight regain (defined by 5 cut points: 0%, 25%, 50%, 75%, and 100%)
Number of subjects: 1561
Study 31594431 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining ≥75% of weight lost
Number of subjects: 1561
Study 28499367 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-needle acupuncture (LA)
Number of subjects: 77
Study 28499367 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture (TA)
Number of subjects: 77
Study 26093910 — intervention group
Group type: EXPERIMENTAL
Intervention: Active magnetic stimulation
Number of subjects: 120
Study 26093910 — intervention group
Group type: COMPARATOR
Intervention: Sham magnetic stimulation
Number of subjects: 120
Study 23017441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable purée-based drink (FVPD)
Number of subjects: 24
Study 23017441 — intervention group
Group type: COMPARATOR
Intervention: Fruit-flavoured sugar-matched control
Number of subjects: 24
Study 21934690 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel/gemcitabine followed by erlotinib (arm A)
Number of subjects: 100
Study 21934690 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib followed by weekly docetaxel/gemcitabine (arm B)
Number of subjects: 100
Study 19258618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 238
Study 19258618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 19258618 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 238
Study 16961695 — intervention group
Group type: EXPERIMENTAL
Intervention: R137696 (1-2 mg)
Number of subjects: 21
Study 16961695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14753731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg
Number of subjects: 653
Study 14753731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study 11426068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipopeptides (mixture of six NEF, GAG, and ENV lipopeptides)
Number of subjects: 28
Study 9436691 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h period of bed rest (Group A)
Number of subjects: 182
Study 9436691 — intervention group
Group type: COMPARATOR
Intervention: 20 min period of bed rest (Group B)
Number of subjects: 182
Study 8273376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversewing plus vagotomy (O+V)
Number of subjects: 120
Study 8273376 — intervention group
Group type: COMPARATOR
Intervention: Gastric resection (GR)
Number of subjects: 120
Study 3304021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO-A) at 15 Hz for 12-203 hours
Number of subjects: 20
Study 3304021 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 20
Study 3304021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO-A)
Number of subjects: 20
Study 31857268 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic medications (aspirin, clopidogrel)
Number of subjects: 347
Study 31857268 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic medications
Number of subjects: 347
Study 31857268 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation medications
Number of subjects: 347
Study 28943002 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 30
Study 28943002 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 26150431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral coping skill training
Number of subjects: 64
Study 26150431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 24626851 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with peginterferon and ribavirin for 12 weeks (SMV12)
Number of subjects: 155
Study 24626851 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with peginterferon and ribavirin for 24 weeks (SMV24)
Number of subjects: 155
Study 22519735 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 19
Study 22519735 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp70
Number of subjects: 19
Study 22519735 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 19
Study 22519735 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin
Number of subjects: 19
Study 21046930 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 12/8 mg)
Number of subjects: 263
Study 21046930 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 3/2 mg)
Number of subjects: 263
Study 21046930 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 6/4 mg)
Number of subjects: 263
Study 21046930 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone 18/12 mg)
Number of subjects: 263
Study 21046930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 18304473 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 28
Study 18304473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adjuvant radiotherapy with androgen deprivation therapy
Number of subjects: 28
Study 18304473 — intervention group
Group type: COMPARATOR
Intervention: Surgical technique
Number of subjects: 28
Study 15710219 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. mixed-micellar phylloquinone (vitamin K1) 10 mg
Number of subjects: 49
Study 15710219 — intervention group
Group type: EXPERIMENTAL
Intervention: oral mixed-micellar phylloquinone (vitamin K1) 10 mg
Number of subjects: 49
Study 15710219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 14500804 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (1-84) 100 microg
Number of subjects: 238
Study 14500804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 238
Study 14500804 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Parathyroid hormone + Alendronate)
Number of subjects: 238
Study 10663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol bolus (1 mg/kg)
Number of subjects: 42
Study 10663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol continuous infusion (150 microg/kg per h)
Number of subjects: 42
Study 10663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl continuous infusion (2 microg/kg per h)
Number of subjects: 42
Study 9065133 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and low-dose aspirin
Number of subjects: 50
Study 9065133 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 50
Study 1381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 165
Study 1381643 — intervention group
Group type: COMPARATOR
Intervention: Cephradine plus metronidazole
Number of subjects: 165
Study 6140541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 2 g orally in divided doses
Number of subjects: 62
Study 6140541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 1 g orally in divided doses
Number of subjects: 62
Study 6140541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 29800322 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene skin wrapping for 1 hour
Number of subjects: 151
Study 29800322 — intervention group
Group type: COMPARATOR
Intervention: Control group (warm cloth after initial care)
Number of subjects: 151
Study 28158276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) for 6 days through a nasointestinal tube.
Number of subjects: 60
Study 28158276 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (education, behavioral strategies, and oral laxatives).
Number of subjects: 60
Study 25998212 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-3803 (test formulation)
Number of subjects: 32
Study 25998212 — intervention group
Group type: COMPARATOR
Intervention: Ovidrel(®) (reference formulation)
Number of subjects: 32
Study 24360521 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted tubularized incised plate urethroplasty (G-TIP)
Number of subjects: 50
Study 24360521 — intervention group
Group type: COMPARATOR
Intervention: Tubularized incised plate urethroplasty (TIP)
Number of subjects: 50
Study 22914365 — intervention group
Group type: EXPERIMENTAL
Intervention: AVX101 (alphavirus replicon HIV-1 subtype C gag vaccine)
Number of subjects: 0
Study 22914365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19634573 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin + repaglinid (2 mg for each meal)
Number of subjects: 60
Study 19634573 — intervention group
Group type: COMPARATOR
Intervention: metformin + glimepirid (3 mg in the morning)
Number of subjects: 60
Study 18036303 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Tertiary Rehabilitation (STR)
Number of subjects: 1365
Study 18036303 — intervention group
Group type: COMPARATOR
Intervention: Routine interventions
Number of subjects: 1365
Study 15631537 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day
Number of subjects: 0
Study 15631537 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium 50 mg/day
Number of subjects: 0
Study 15631537 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg/day
Number of subjects: 0
Study 15631537 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg/day
Number of subjects: 0
Study 12092918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 20
Study 10546018 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV analysis in diabetic children aged > or = 11 years
Number of subjects: 73
Study 10546018 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV analysis in younger diabetic patients
Number of subjects: 73
Study 10546018 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness duration and microalbuminuria
Number of subjects: 73
Study 7496291 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 7496291 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomised trials
Number of subjects: 0
Study 7496291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort studies
Number of subjects: 0
Study 2107112 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy plus air contrast barium enema
Number of subjects: 380
Study 2107112 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 380
Study 573222 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-glycerophosphate
Number of subjects: 6
Study 573222 — intervention group
Group type: EXPERIMENTAL
Intervention: linoleic acid
Number of subjects: 6
Study 573222 — intervention group
Group type: EXPERIMENTAL
Intervention: purified soybean lecithin
Number of subjects: 6
Study 573222 — intervention group
Group type: EXPERIMENTAL
Intervention: soybean lecithin plus cholic acid
Number of subjects: 6
Study 31947529 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (9 mg daily for 3 months)
Number of subjects: 69
Study 31947529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 3 months)
Number of subjects: 69
Study 30920398 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 84
Study 30920398 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 84
Study 30920398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both steroid injection and KT
Number of subjects: 84
Study 30920398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 28524341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Number of subjects: 224
Study 28524341 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg b.i.d., clarithromycin 500 mg b.i.d., and omeprazole 40 mg b.i.d. for 14 days
Number of subjects: 224
Study 25881035 — intervention group
Group type: EXPERIMENTAL
Intervention: Public reporting of prescribed ranking information
Number of subjects: 600
Study 25881035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no public reporting)
Number of subjects: 600
Study 24034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Number of subjects: 62
Study 24034910 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 62
Study 21525158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3346
Study 21525158 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3346
Study 21525158 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels
Number of subjects: 3346
Study 19038501 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (4.5mg/kg/min, 2300-0700h)
Number of subjects: 20
Study 19038501 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 20
Study 16575410 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (P)
Number of subjects: 41
Study 16575410 — intervention group
Group type: COMPARATOR
Intervention: Non-posturing (NP)
Number of subjects: 41
Study 14991313 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL implantation (intraocular lens implantation)
Number of subjects: 0
Study 14991313 — intervention group
Group type: COMPARATOR
Intervention: Control group (seniors without cataract surgery)
Number of subjects: 0
Study 11801830 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 40
Study 11801830 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 30 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 60 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at 0.9 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP at 0.8 pmol . kg‐1 . min‐1 + ex(9‐39)NH2 at 300 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 9525985 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 at 0.3 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 9525985 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 at 0.9 pmol . kg‐1 . min‐1
Number of subjects: 6
Study 8306218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline (2 units/mL)
Number of subjects: 78
Study 8306218 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 78
Study 8306218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 78
Study 2917588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 18
Study 2917588 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 18
Study 2917588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1098495 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin (600 mg daily)
Number of subjects: 0
Study 1098495 — intervention group
Group type: COMPARATOR
Intervention: Oral dapsone (100 mg daily)
Number of subjects: 0
Study 1098495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular acedapsone (225 mg every 12 weeks)
Number of subjects: 0
Study 1098495 — intervention group
Group type: COMPARATOR
Intervention: Oral dapsone (50 mg daily)
Number of subjects: 0
Study 1098495 — intervention group
Group type: EXPERIMENTAL
Intervention: BL patients
Number of subjects: 0
Study 1098495 — intervention group
Group type: EXPERIMENTAL
Intervention: LL patients
Number of subjects: 0
Study 31416698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal atomization (INA) of medetomidine (40 μg kg‐1)
Number of subjects: 18
Study 31416698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal drops (IND) of medetomidine (40 μg kg‐1)
Number of subjects: 18
Study 31416698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection of medetomidine (40 μg kg‐1)
Number of subjects: 18
Study 28884566 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol medium-long chain lipid emulsion injection (100 mg initial dose, then 0.54 mg/kg/h for 24 hours)
Number of subjects: 87
Study 28884566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sedative measures)
Number of subjects: 87
Study 23812665 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 0
Study 23812665 — intervention group
Group type: COMPARATOR
Intervention: Waitlist ASD group
Number of subjects: 0
Study 23154587 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan add-on therapy
Number of subjects: 46
Study 23154587 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB group
Number of subjects: 46
Study 21884874 — intervention group
Group type: EXPERIMENTAL
Intervention: Late high-degree atrioventricular block (HAVB) documented by continuous ECG monitoring occurring more than 3 weeks after AMI
Number of subjects: 286
Study 19620917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary training (high-intensity sprint-training regime consisting of 7 to 15 repeats of badminton-specific sprints twice per week)
Number of subjects: 12
Study 19620917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary training
Number of subjects: 12
Study 19620917 — intervention group
Group type: COMPARATOR
Intervention: Regular training (4 2-hour sessions per week)
Number of subjects: 12
Study 19620917 — intervention group
Group type: COMPARATOR
Intervention: Regular training
Number of subjects: 12
Study 16681772 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 expression in ULMS
Number of subjects: 25
Study 16681772 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFR expression in ULMS
Number of subjects: 25
Study 16681772 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis based on p53 expression in ULMS
Number of subjects: 25
Study 16681772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor stage in ULMS
Number of subjects: 25
Study 14579914 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 700
Study 14579914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 700
Study 10872434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic index of New Zealand foods
Number of subjects: 28
Study 9166304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-g single oral dose of metronidazole
Number of subjects: 164
Study 9166304 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g single oral dose of metronidazole
Number of subjects: 164
Study 9166304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g single oral dose of metronidazole
Number of subjects: 164